Business Expansions, Collaborations, and Strong Sales Boost Growth - Research Report on HCA, PetMed Express, Chemed, USANA, and Auxilium

NEW YORK, July 25, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting HCA Holdings Inc. (NYSE: HCA), PetMed Express Inc. (NASDAQ: PETS), Chemed Corporation (NYSE: CHE), USANA Health Sciences, Inc. (NYSE: USNA), and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

HCA Holdings Inc. Research Report

On July 18, 2013, HCA Holdings Inc. (HCA) announced that the Company's West Florida Division will buy three Tampa Bay hospitals, namely Palms of Pasadena Hospital, Memorial Hospital of Tampa, and Town & Country Hospital from IASIS Healthcare LLC (IASIS). According to the HCA, Palms of Pasadena Hospital is a 307-bed facility in St. Petersburg, while Memorial Hospital of Tampa and Town & Country Hospital are both located in Tampa and have 183 and 201 beds, respectively. Peter A. Marmerstein, President of HCA West Florida, said, "Palms of Pasadena Hospital, Memorial Hospital of Tampa and Town & Country Hospital have strong traditions of caring for their communities for many years. These hospitals will enhance our ability to serve patients throughout the Tampa Bay and St. Petersburg area, and we look forward to welcoming them to HCA West Florida." The Full Research Report on HCA Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/HCA]

PetMed Express Inc. Research Report

On July 22, 2013, PetMed Express Inc. (PetMed Express) reported its financial results for Q1 FY 2014 (period ended June 30, 2013). Net sales increased 7.6% YoY to $74.2 million. Net income was $4.8 million or $0.24 per diluted share in Q1 FY 2014 compared to net income of $4.0 million or $0.20 per diluted share in Q1 FY 2013. Menderes Akdag, President and Chief Executive Officer of PetMed Express, said, "We are pleased with the strong new order and reorder sales for the quarter. Our sales increase for the quarter was also highlighted by an increased average order size - $77 for the quarter ended June 30, 2013 compared to $73 for the same quarter in the prior year." He added, "For the remainder of Fiscal 2014 we are focusing on improving our advertising efficiency and continuing to expand our product offerings." The Full Research Report on PetMed Express Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/PETS]

Chemed Corporation Research Report

On July 18, 2013, Chemed Corporation (Chemed) reported its financial results for Q2 2013. Consolidated revenues increased 0.9% YoY to $357.2 million. Consolidated net income was $14.6 million or $0.77 per diluted share compared to $21.3 million or $1.10 per diluted share in Q2 2012. For VITAS Healthcare Corporation (VITAS), a segment of Chemed, net revenue declined 0.6% YoY to $263.6 million. VITAS' net income increased 0.3% YoY to $20.5 million. Additionally, sales in its Roto-Rooter division increased 5.3% YoY to $93.6 million in Q2 2012. Roto-Rooter's net income was $1.4 million, down 82.5% YoY (including a litigation settlement). The Full Research Report on Chemed Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/CHE]

USANA Health Sciences, Inc. Research Report

On July 15, 2013, USANA Health Sciences, Inc. (USANA) announced the opening of a new office in Bogota, Colombia. According to the Company, the new opening establishes its presence in Colombia, its 19th market worldwide. Carlo Ledezma, USANA's General Director of Mexico, said, "Opening business in Colombia is a perfect choice for USANA due to the strong connections we already have to the country from our outstanding leaders in Mexico. We can see huge opportunities for growth in this market since Colombia is one of the largest Spanish-speaking countries in the world and has become strong in the direct selling arena. Plus, there is a critical need for essential nutrients in this part of the world." USANA also reported that Colombia is the third leading market in Latin America and 16th overall direct sales market. The Full Research Report on USANA Health Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/USNA]

Auxilium Pharmaceuticals, Inc. Research Report

On July 16, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) and Swedish Orphan Biovitrum AB (Sobi) announced that they have entered into a long-term agreement for the development, supply, and commercialization of XIAPEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the treatment of Dupuytren's contracture. Further, Auxilium said that work is currently ongoing to file for approval of XIAPEX for the treatment of Peyronie's disease in the EU. Under the terms of the agreement, Auxilium said that Sobi will receive exclusive rights to commercialize XIAPEX for these two indications, subject to applicable regulatory approvals, in 28 EU member countries, Switzerland, Norway, Iceland, 18 Central Eastern Europe/Commonwealth of Independent countries, including Russia and Turkey, and 22 Middle Eastern and North African countries. Auxilium will also receive significant tiered double-digit royalties based on sales of XIAPEX in Sobi's territories, which will also cover payment for product supply. Additionally, Auxilium said that Sobi could make up to $40 million in potential sales milestone payments to Auxilium.The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/AUXL]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports